Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA "Complete Response" On Toremifene Moves The Goal Posts, GTx CEO Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GTx was taken by surprise with FDA's decision to issue a "complete response" letter for the firm's selective estrogen receptor modulator toremifene 80 mg - a drug whose clinical development program was designed with the agency's help under a Special Protocol Assessment

You may also be interested in...

Getting Past FDA's HALT: Can Amgen Escape New Trial Requirement For Prolia With Data From SRE Studies?

Amgen will attempt to use data culled from its trials of Prolia (denosumab) in reducing skeletal-related events to resolve FDA's questions about the drug's effects in cancer patients, raised in the agency's "complete response" letter on d-mab's use in treating patients with bone loss due to hormone ablation therapy

FDA Says "Agreement" Does Not Have To Be Holy Grail Of SPA Discussions

The next reauthorization of the Special Protocol Assessment process could de-emphasize the idea that an SPA is an "agreement" with FDA

Amgen’s Denosumab, GTx’s Toremifene Keep Pace At ASCO On Prevention Of Bone Fractures In Prostate Cancer Patients

Both firms have October user fee dates for prevention of bone fracture risk in prostate cancer patients on androgen deprivation therapy, and both report favorable incremental data.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts